Innogenetics gets early favorable judgment in patent infringement suit

By Elaine Rigoli

Tampa, Fla., Aug. 29 - The District Court of the Western District of Wisconsin has ruled that Abbott Laboratories' hepatitis C virus genotyping products infringe at least claims one through three of Innogenetics NV's hepatitis C virus genotyping patent (U.S. Patent No. 5,846,704).

Abbott is currently presenting its arguments of invalidity of Innogenetics' hepatitis C virus genotyping patent. A final decision on Abbott's defenses on these aspects is expected soon. Innogenetics is a biopharmaceutical company based in Gent, Belgium.

Abbott is a pharmaceutical company based in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.